2b乔巴发琴无力罗宾彩色_日韩欧美理论一级片_日韩欧美中文字幕在_韩国三级在线不卡播放_美女靠逼软件_99无码蜜臀人妻久久精品_九九精品亚洲视频_国产大学生闺蜜AV在线播放_主人给我戴上奶牛榨乳器调教_被灌满精子的波多野结衣

On the evening of June 20, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration, indicating that its clinical trial application for "Human Interferon α2b Vaginal Effervescent Capsule" was accepted.

Basic Information of Drug for Registration

1. Product Name: Human Interferon α2b Vaginal Effervescent Capsule
2. Application Item: clinical trial for registration of drugs produced in China
3. Indication: It is proposed for the treatment of cervicitis caused by virus, with or without vaginitis.
4. Dosage Form: Capsule

The promotion of the R&D of Human Interferon α2b Vaginal Effervescent Capsules will help the Company enrich the dosage forms of interferon products, strengthen its competitiveness in the antiviral field, improve the overall R&D capacity, and enhance the long-term profitability.

About Human Interferon α2b Vaginal Effervescent Capsule

Interferon has a good therapeutic effect on chronic cervicitis. The common dosage forms thereof are effervescent capsule and effervescent tablet. Effervescent capsule achieves better compliance than effervescent tablet. The Human Interferon α2b Vaginal Effervescent Capsule developed by Kexing Biopharm is proposed to treat cervicitis caused by virus, with or without vaginitis, and its registration classification is Class 2.2 therapeutic biological products (defined as those adding new indications that have not been approved in China and abroad or changing the target population).